title: Adapting smoking cessation treatment according to initial response to precessation nicotine patch.
abstract: OBJECTIVE The authors evaluated an adaptive smoking cessation treatment strategy in which nicotine patch treatment was initiated before a quit date, and then, depending on initial therapeutic response, either the nicotine patch was continued or alternative pharmacotherapies were provided. METHOD The study was a double-blind, parallel-arm adaptive treatment trial. A total of 606 cigarette smokers started open-label nicotine patch treatment 2 weeks before the quit date. Those whose ad lib smoking did not decrease by &gt;50% after 1 week were randomly assigned to one of three double-blind treatments: nicotine patch alone (control condition); "rescue" treatment with bupropion augmentation of the patch; or rescue treatment with varenicline alone. Participants whose precessation smoking decreased &gt;50% but who lapsed after the quit date were also randomly assigned to the two rescue treatments or to nicotine patch alone. Logistic regression analyses compared each rescue treatment against the control condition in terms of abstinence at the end of treatment (weeks 8-11) and at 6 months. RESULTS Smokers who did not respond adequately to precessation nicotine patch benefited from bupropion augmentation; abstinence rates at end of treatment were 16% with nicotine patch alone and 28% with bupropion augmentation (odds ratio=2.04, 95% CI=1.03-4.01). Switching to varenicline produced less robust effects, but point abstinence at 6 months was 6.6% with the patch alone and 16.5% with a switch to varenicline (odds ratio=2.80, 95% CI=1.11-7.06). Postquit adaptive changes in treatment had no significant effects on any abstinence outcome. CONCLUSIONS It is possible to rescue a significant portion of smokers who would have failed to achieve abstinence if left on nicotine patch alone by identifying these smokers before their quit date and implementing adaptive changes in treatment.
authors: Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA. (jed.rose@duke.edu
authors: Jed E
authors: JE
authors: Rose
authors: Frédérique M
authors: FM
authors: Behm
mesh_terms: D000328:Adult; D001552:Benzazepines / Q000008:administration & dosage / Q000009:adverse effects; D016642:Bupropion / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D018765:Dopamine Uptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D004311:Double-Blind Method; D004357:Drug Synergism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018722:Nicotinic Agonists / Q000008:administration & dosage / Q000009:adverse effects; D011292:Premedication; D011810:Quinoxalines / Q000008:administration & dosage / Q000009:adverse effects; D016540:Smoking Cessation / Q000379:methods*; D061485:Tobacco Use Cessation Devices / Q000009:adverse effects; D014029:Tobacco Use Disorder / Q000628:therapy*; D016896:Treatment Outcome; D000068580:Varenicline
chemical_list: D001552:Benzazepines; D018765:Dopamine Uptake Inhibitors; D018722:Nicotinic Agonists; D011810:Quinoxalines; D016642:Bupropion; D000068580:Varenicline
references: Arch Gen Psychiatry. 2008 Jun;65(6):683-93
references: 18519826
references: J Subst Abuse Treat. 2008 Jun;34(4):426-32
references: 17869475
references: JAMA. 1995 Nov 1;274(17):1353-8
references: 7563559
references: Eur J Clin Pharmacol. 2003 Dec;59(10):767-73
references: 14615857
references: Respir Care. 2000 Oct;45(10):1196-9
references: 11203101
references: J Clin Oncol. 2003 Mar 1;21(5):914-20
references: 12610193
references: Arch Intern Med. 1997 Feb 10;157(3):335-40
references: 9040302
references: Nicotine Tob Res. 2006 Feb;8(1):89-101
references: 16497603
references: PLoS One. 2011;6(11):e27016
references: 22073240
references: JAMA. 2006 Jul 5;296(1):56-63
references: 16820547
references: JAMA. 1995 Nov 1;274(17):1347-52
references: 7563558
references: Biol Psychiatry. 2011 Jun 1;69(11):1017-8
references: 21550436
references: Mol Med. 2010 Jul-Aug;16(7-8):247-53
references: 20379614
references: Nicotine Tob Res. 2009 Sep;11(9):1067-75
references: 19567826
references: JAMA. 1994 Feb 23;271(8):589-94
references: 8301790
references: CMAJ. 2011 Sep 6;183(12):1359-66
references: 21727225
references: Arch Intern Med. 2006 Aug 14-28;166(15):1571-7
references: 16908789
references: JAMA. 2006 Jul 5;296(1):47-55
references: 16820546
references: Arch Intern Med. 2004 Sep 13;164(16):1797-803
references: 15364675